Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: MOLECULAR EXPRESS, INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2023-09-30 to 2025-09-29
Current total value of award: $599925
Description: DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.